Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Daan G Knapen"'
Autor:
Elisabeth GE de Vries, Marjolijn N Lub-de Hooge, Sjoukje F Oosting, Pim P van de Donk, Daan G Knapen, Anthonie J van der Wekken, Adrienne H Brouwers, Derk-Jan A de Groot
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patient
Externí odkaz:
https://doaj.org/article/1c4117e2a0ec420c864e6d697316ea5b
Autor:
Daan G. Knapen, Sara Hone Lopez, Derk Jan A. de Groot, Jacco-Juri de Haan, Elisabeth G. E. de Vries, Rodrigo Dienstmann, Steven de Jong, Arkajyoti Bhattacharya, Rudolf S. N. Fehrmann
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-10 (2024)
Abstract Background Bulk transcriptional profiles of early colorectal cancer (CRC) can fail to detect biological processes associated with disease-free survival (DFS) if the transcriptional patterns are subtle and/or obscured by other processes’ pa
Externí odkaz:
https://doaj.org/article/8d7f690e987c46dca2d0be26c8c98c2b
Autor:
Linda N. Broer, Daan G. Knapen, Derk-Jan A. de Groot, Peter G.M. Mol, Jos G.W. Kosterink, Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge
Publikováno v:
iScience, Vol 27, Iss 6, Pp 110115- (2024)
Summary: Monoclonal antibodies are important cancer medicines. The European Medicines Agency (EMA) approved 48 and the Food and Drug Administration (FDA) 56 anticancer monoclonal antibody-based therapies. Their high prices burden healthcare systems a
Externí odkaz:
https://doaj.org/article/cbbec29fb32247bf84c0de6ad6bf2e14
Autor:
Herman J. Woerdenbag, Peter Olinga, Ellen A. Kok, Donald A. P. Brugman, Ulrike F. van Ark, Arwin S. Ramcharan, Paul W. Lebbink, Frederik J. H. Hoogwater, Daan G. Knapen, Derk Jan A. de Groot, Maarten W. Nijkamp
Publikováno v:
Cancers, Vol 15, Iss 7, p 2119 (2023)
The application of cannabis products in oncology receives interest, especially from patients. Despite the plethora of research data available, the added value in curative or palliative cancer care and the possible risks involved are insufficiently pr
Externí odkaz:
https://doaj.org/article/37182b780841423cbcc8666e1a04e7f0
Autor:
Daan G. Knapen, Jacco J. de Haan, Rudolf S.N. Fehrmann, Elisabeth G.E. de Vries, Derk Jan A. de Groot
Publikováno v:
Critical Reviews in Oncology/Hematology. 183
There is a clear unmet need to improve early colon cancer management. This review encompasses the current systemic treatment landscape and summarises novel and pivotal trials. The Immunoscore and circulating tumour DNA (ctDNA) are studied to evaluate
Autor:
Pim P. van de Donk, Lotte M. Smit, Joyce van Sluis, Wim Timens, Adrienne H. Brouwers, Marjolijn N. Lub- de Hooge, Sjoerd G. Elias, Jourik A. Gietema, Claudia A. van Winkel, JuAn Wang, Jason Giurleo, Thomas Uldrick, Hung Kam Cheung, Hilde Jalving, Sjoukje F. Oosting, Daan G. Knapen, Derk-Jan A. de Groot, Elisabeth G. de Vries
Publikováno v:
Cancer Research. 83:5611-5611
Background Immune checkpoint inhibitors (ICIs) can induce durable responses in multiple different tumor types. Lymphocyte activation gene-3 (LAG-3) is one of the immune checkpoints for which therapeutic antibodies are being developed. PET imaging wit
Autor:
Pim P van de Donk, Sjoukje F Oosting, Daan G Knapen, Anthonie J van der Wekken, Adrienne H Brouwers, Marjolijn N Lub-de Hooge, Derk-Jan A de Groot, Elisabeth GE de Vries
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004949
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patient
Autor:
Linda N Broer, Daan G Knapen, Frans Valentijn Suurs, Ingrid Moen, Danique Giesen, Stijn J H Waaijer, Baard Indrevoll, Christine Ellingsen, Alexander Kristian, Alan S Cuthbertson, Derk-Jan A de Groot, Patricia E Cole, Elisabeth G.E. de Vries, Urs B Hagemann, Marjolijn N Lub - de Hooge
Publikováno v:
The Journal of Nuclear Medicine, 63(11), 1715-1721. SOC NUCLEAR MEDICINE INC
Rationale: Mesothelin targeted thorium-227 conjugate (227Th-MSLN) is a novel targeted alpha therapy developed to treat mesothelin overexpressing cancers. We radiolabeled the same antibody-chelator conjugate with zirconium-89 (89Zr-MSLN) to evaluate i
Autor:
Urania Dafni, Nathan I. Cherny, Nicola Jane Latino, Jean-Yves Douillard, Daan G Knapen, Panagiota Zygoura, Derk Jan A. de Groot, Elisabeth G.E. de Vries
Publikováno v:
ESMO Open, 5(5):e000681. BMJ PUBLISHING GROUP
ESMO Open
ESMO Open, Vol 5, Iss 5 (2020)
ESMO Open
ESMO Open, Vol 5, Iss 5 (2020)
Click here to listen to the Podcast BACKGROUND: Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) serves to grade therapies with curative intent. Hitherto only few trials with curative intent have bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de6f6194e19c0509ba4207adf58f364c
https://research.rug.nl/en/publications/590c3cf2-ea12-4d66-97aa-86eb8642fce9
https://research.rug.nl/en/publications/590c3cf2-ea12-4d66-97aa-86eb8642fce9
Autor:
Elisabeth G.E. de Vries, Emmy I. M. Meijne, Daan G Knapen, Derk Jan A. de Groot, Thomas C. Kwee, Rudolf S N Fehrmann
Publikováno v:
CANCER TREATMENT REVIEWS. 87
Immune checkpoint inhibitors (ICI) have improved outcomes for patients with advanced cancers, and results in increasing numbers of long-term survivors. For registration studies, progression-free survival and disease-free survival often serve as prima